Phase i clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 3, 2009, Pages 441-450

  Krishnamurthi, Smitha S ^a,b   Brell, Joanna M ^a,b   Hoppel, Charles L ^a,b   Egorin, Merrill J ^c   Weaver, Karen C ^a   Li, Xiaolin ^a,b   Ingalls, Stephen T ^a,b   Zuhowski, Eleanor G ^c   Schluchter, Mark D ^a   Dowlati, Afshin ^a,b   Cooney, Matthew M ^a,b   Gibbons, Joseph ^a,b   Overmoyer, Beth A ^a,b   Ivy, S Percy ^d   Remick, Scot C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Capecitabine; Chemotherapy; Irinotecan; Oxaliplatin; Phase I study

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; DOXIFLURIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANK SUM TEST; SEX DIFFERENCE; SOLID TUMOR; STATISTICAL SIGNIFICANCE; STOMACH CANCER; VOMITING; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 58249134119     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0754-2     Document Type: Article

References (44)

1. D Cunningham S Pyrhonen RD James CJ Punt TF Hickish R Heikkila TB Johannesen H Starkhammar CA Topham L Awad C Jacques P Herait 1998 Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1413 1418 (Pubitemid 28510874)
2. P Rougier E Van Cutsem E Bajetta N Niederle K Possinger R Labianca M Navarro R Morant H Bleiberg J Wils L Awad P Herait C Jacques 1998 Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1407 1412 (Pubitemid 28510873)
3. D Machover E Diaz-Rubio A de Gramont A Schilf JJ Gastiaburu S Brienza M Itzhaki G Metzger D N'Daw J Vignoud A Abad E Francois E Gamelin M Marty J Sastre JF Seitz M Ychou 1996 Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann Oncol 7 95 98 (Pubitemid 26051870)
4. ML Rothenberg AM Oza RH Bigelow JD Berlin JL Marshall RK Ramanathan LL Hart S Gupta CA Garay BG Burger N Le Bail DG Haller 2003 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059 2069 (Pubitemid 46606353)
5. A de Gramont J Vignoud C Tournigand C Louvet T Andre C Varette E Raymond S Moreau N Le Bail M Krulik 1997 Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer Eur J Cancer 33 214 219 (Pubitemid 27117717)
6. E Diaz-Rubio J Sastre A Zaniboni R Labianca H Cortes-Funes F de Braud C Boni M Benavides G Dallavalle M Homerin 1998 Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study Ann Oncol 9 105 108 (Pubitemid 28125772)
7. F Levi JL Misset S Brienza R Adam G Metzger M Itzakhi JP Caussanel F Kunstlinger S Lecouturier A Descorps-Declere 1992 A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer Cancer 69 893 900
8. F Bertheault-Cvitkovic A Jami M Ithzaki PD Brummer S Brienza R Adam F Kunstlinger H Bismuth JL Misset F Levi 1996 Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer J Clin Oncol 14 2950 2958 (Pubitemid 26371453)
9. JY Douillard D Cunningham AD Roth M Navarro JP Karasek P Jandik J Carmichael M Alaki G Gruia L Awad P Rougier 2006 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial Lancet 355 1041 1047 (Pubitemid 43088543)
10. LB Saltz JV Cox C Blanke LS Rosen L Fehernbacher M Moore JA Maroun SP Ackland PK Lockre N Pirotta GL Elfring LL Miller 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer NEJM 343 905 914
11. JA Houghton PJ Cheshire JD Hallman L Lutz X Luo Y Li PJ Houghton 1996 Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma Clin Cancer Res 2 107 118 (Pubitemid 26042185)
12. S Guichard I Hennebelle R Bugat P Canal 1998 Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line Biochem Pharmacol 55 667 676 (Pubitemid 28077825)
13. E Raymond C Buquet-Fagot S Djelloul J Mester E Cvitkovic P Allain C Louvet C Gespach 1997 Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anticancer Drugs 8 876 885 (Pubitemid 27487802)
14. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiulo R, Focan C, Letourneau Y, Chollet P, Llory JF, Coudet B, Bertheault-Cvitkovic F, Adam R, Le Baif N, Misset JL, Bayssas M, Levi F(1997) Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) (Meeting abstract). Proc Am Soc Clin Oncol 16, abstract 805
15. Gramont A d, Figer A, Seymour M, Homerin M, Bail NI, Cassidy J, Boni C, Cortes-Funes H, Freyer G, Hendler D, Louvet C(1998) A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without axaliplatin in advanced colorectal cancer (CRC) (Meeting abstract). Proc Am Soc Clin Oncol 17, abstract 985
16. JT Reardon A Vaisman SG Chaney A Sancar 1999 Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res 59 3968 3971 (Pubitemid 29393563)
17. N Kemeny W Tong M Gonen J Stockman C Di Lauro J Teitcher P White C Price L Saltz S Sharma MA Graham 2002 Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer Ann Oncol 13 1490 1496
18. N Zeghari-Squalli E Raymond E Cvitkovic F Goldwasser 1999 Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin Clin Cancer Res 5 1189 1196 (Pubitemid 29233237)
19. Buechele T, Schoeber C, Kroening H, Eckart M, Lingenfelser T, Respondek M, Stier G, Balleisen L, Kallen KJ, Schmidt J, Pasold R, Spohn C, Hurtz HJ, Graubner M, Schmoll HJ (1998) Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (pts) with advanced colorectal cancer (CRC): a preliminary report (Meeting abstract). Proc Am Soc Clin Oncol 17, abstract 1106
20. M Moehler T Hoffmann K Hildner J Siebler PR Galle M Heike 2002 Weekly oxaliplatin, high-dose folinic acid and 24 h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens Z Gastroenterol 40 957 964 (Pubitemid 36033760)
21. Meta-analysis Group in Cancer 1998 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 301 308 (Pubitemid 28041613)
22. K Chansky J Benedetti JS Macdonald 2005 Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma Cancer 103 1165 1171 (Pubitemid 40328086)
23. JA Sloan RM Goldberg DJ Sargent D Vargas-Chanes S Nair SS Cha PJ Novotny MA Poon MJ O'Connell CL Loprinzi 2002 Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer J Clin Oncol 20 1491 1498 (Pubitemid 34260527)
24. Thomas R, Quinn M, Wilson R, Floeter M, Lehky T, Saif MW, Hamilton JM, Monahan B, Grochow L, Harold N, Schull B, Allegra C, Cliatt J, Grem J (2001) A phase I trial of capecitabine (Cape) and oxaliplatin (OHP). Proc Am Soc Clin Oncol 22, abstract 530
25. K Erkmen MJ Egorin LM Reyno R Morgan Jr JH Doroshow 1995 Effects of storage on the binding of carboplatin to plasma proteins Cancer Chemother Pharmacol 35 254 256
26. P de Bruijn J Verweij WJ Loos K Nooter G Stoter A Sparreboom 1997 Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection J Chromatogr B Biomed Sci Appl 698 277 285 (Pubitemid 27412531)
27. I Barilero D Gandia JP Armand A Mathieu-Boue M Re A Gouyette GG Chabot 1992 Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients J Chromatogr 575 275 280
28. B Reigner S Clive J Cassidy D Jodrell R Schulz T Goggin L Banken B Roos M Utoh T Mulligan E Weidekamm 1999 Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients Cancer Chemother Pharmacol 43 309 315 (Pubitemid 29075888)
29. DR Budman NJ Meropol B Reigner PJ Creaven SM Lichtman E Berghorn J Behr RJ Gordon B Osterwalder T Griffin 1998 Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine J Clin Oncol 16 1795 1802 (Pubitemid 28234724)
30. B Reigner J Verweij L Dirix J Cassidy C Twelves D Allman E Weidekamm B Roos L Banke M Utoh B Osterwalder 1998 Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients Clin Cancer Res 4 941 948 (Pubitemid 28183395)
31. ML Rocci Jr WJ Jusko 1983 LAGRAN program for area and moments in pharmacokinetic analysis Comput Programs Biomed 16 203 216
32. RA Walgren MA Meucci HL [tmp] McLeod 2005 Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol 23 7342 7349 (Pubitemid 46202347)
33. Goetz MP, Reid JM, Safgren SL, Mandrekar SJ, Erlichman C, Adjei AA, Goldberg RM, Grothey A, McWilliams RR, Ames MM (2007) UGT1A128 genotype determines the maximum tolerated dose (MTD) and pharmacokinetics (PK) of irinotecan-based chemotherapy: A phase I dose escalation trial. 2007 Gastrointestinal Cancers Symposium PROGRAM/PROCEEDINGS, abstract 235
34. HC Pitot RM Goldberg JM Reid JA Sloan PA Skaff C Erlichman J Rubin PA Burch AA Adjei SA Alberts LJ Schaaf G Elfring LL Miller 2000 Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy Clin Cancer Res 6 2236 2244 (Pubitemid 30399189)
35. RH Mathijssen RJ van Alphen J Verweij WJ Loos K Nooter G Stoter A Sparreboom 2001 Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2182 2194 (Pubitemid 32751614)
36. M Mackean A Planting C Twelves J Schellens D Allman B Osterwalder B Reigner T Griffin S Kaye J Verweij 1998 Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J Clin Oncol 16 2977 2985 (Pubitemid 28417417)
37. O Soepenberg H Dumez J Verweij D Semiond MJ de Jonge FA Eskens J Ter Steeg J Selleslac S Assadourian GJ Sanderink A Sparreboom AT van Oosterom 2005 Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors J Clin Oncol 23 889 898 (Pubitemid 46224190)
38. H Ebi Y Sigeoka T Saeki K Kawada T Igarashi N Usubuchi R Ueda Y Sasaki H Minami 2005 Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR) Cancer Chemother Pharmacol 56 205 211 (Pubitemid 40884276)
39. C Tournigand T Andre E Achille G Lledo M Flesh D Mery-Mignard E Quinaux C Couteau M Buyse G Ganem B Landi P Colin C Louvet A de Gramont 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 (Pubitemid 41095086)
40. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts MA Schwartz AB Benson 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 (Pubitemid 46733080)
41. W Scheithauer GV Kornek M Raderer B Schull K Schmid E Kovats B Schneeweiss F Lang A Lenauer D Depisch 2003 Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 1307 1312 (Pubitemid 46606408)
42. ME Burge D Smith C Topham DP Jackson DA Anthoney F Halstead MT Seymour 2006 A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma Br J Cancer 94 1281 1286
43. RM Goldberg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot SR Alberts 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 (Pubitemid 41095110)
44. S Cao FA Durrani YM Rustum 2005 Synergistic antitumor activity of capecitabine in combination with irinotecan Clin Colorectal Cancer 4 336 343 (Pubitemid 40309381)